- Site to Provide Fluorodeoxyglucose (F-18 FDG) for use in Earlier Detection of Disease and Therapy Management
MDS Nordion, a leading global provider of medical isotopes and
radiopharmaceuticals used in molecular medicine, today announced the opening
of a facility in Fleurus,
PET imaging produces a three-dimensional image, or picture, of functional
processes in the body, such as brain activity, and is a highly accurate and
effective method of diagnosing disease and managing patient therapy. MDS
Nordion's new facility will provide timely supply of F-18 FDG to hospitals
throughout
'Customers count on MDS Nordion for leadership, quality products and
customized services,' said
The PET imaging market is the most rapidly growing area of nuclear
medicine and procedures. Statistics from a recent Medical Options survey
indicates PET examinations are on a rapid rise in
'PET imaging is effective because it allows early detection of tumours,
as well as assessment of therapeutic strategies,' said Professor
About MDS Nordion
MDS Nordion, a business unit of MDS Inc., is a global leader in providing medical isotopes for molecular and diagnostic imaging, radiotherapeutics and sterilization technologies for medical products that benefit the lives of millions of people in more than 50 countries around the world. MDS Nordion's products and services are used on a daily basis by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Find out more at http://www.mdsnordion.com
About MDS
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com.
SOURCE MDS
